Evolution: Miniproteins appeared from nowhere scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.
This ERC Advanced Grant is awarded to scientists with more than ten years of research experience who have already played a prominent role in their field.
Scientists have developed a therapeutic agent to treat heart failure caused by the stiffening of the walls of the chambers of the heart that prevents adequate filling of the chambers even when the pumping activity of the heart is normal. This form of heart failure has no available treatment at present. The authors have targeted a splicing factor that regulates the splicing of titin, a protein that regulates the elasticity of the heart walls.
Location of receptors is decisive miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Leducq Foundation provides $7 million to support Cardiac Splicing as a Therapeutic Target project
Diverse messenger RNAs are produced in cells by “alternative splicing.” The Leducq Foundation is now supporting a transatlantic network dedicated to investigating this process in heart muscle cells and how changes in this process contribute to disease. Professor Michael Gotthardt of the MDC and Professor Leslie Leinwand of the University of Colorado Boulder are coordinating the project.
Despite advances in prevention and therapy, cardiovascular diseases are still one of the leading causes of death worldwide. Scientists have only recently begun to understand the key role of alternative splicing - the stitching together of messenger RNA during gene transcription - in cardiovascular diseases. The Leducq Foundation is providing 7 million U.S. dollars over the next five years to support the Cardiac Splicing as a Therapeutic Target (CASTT) project, which is comprised of six European a